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from a cumulative of 73 per 10.000 patient-days to a rate of
23.8 per 10.000 patient-days, with no new cases during the
last month of surveillance.
Conclusion: A multidisciplinary approach to decrease rates
of CDI including: education, enhanced environmental
cleaning with review and feedback, and standard use of UVC
pulsed technology was effective to reduce the rates of CDI in
a bone marrow transplant unit.367
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Growth factors are routinely used after autologous
transplantation to shorten the duration of neutropenia.
Tbo-ﬁlgrastim (TBO) was recently approved in the U.S. for
patients with non-myeloid malignancies. The Average
Wholesale Price for TBO is 20% less than Filgrastim (FGS).
Whether TBO is comparable to FGS for reducing time to
engraftment following HSCT is unknown. A cost-savings
initiativewas undertaken at NorthwesternMemorial Hospital
to substitute TBO for FGS in all autografts. Herein are the re-
sults of an observational study which compares TBO and FGS.
FGS patients were treated from10/2013-4/14/2014 and TBO
patients between 4/15/14-9/20/2014. All patients were
treated for multiple myeloma with melphalan 200mg/m2.
TBO and FGS were initiated day+5 after stem cell infusion,
and discontinued the ﬁrst day the absolute neutrophil
exceeded 1000/ml. Time to engraftment was deﬁned as
the number of days from stem cell re-infusion until the
ﬁrst day the ANC exceeded 500cell/ml. TBO and FGS dose
was rounded as follows: <80kg received 300mcg/day,
>80mg<120kg received 480mcg and those >120kg received
600mcg/day.
96 consecutively treatedpatientswere included-48 treated
with TBO and 48 treated with FGS. No signiﬁcant differenceTable 1
Filgrastim versus TBO-ﬁlgrastim
Characteristic (median/range) Filgrastim TBO-Filgastim P-value
Number 48 48
Age 57(42-69) 59(38-69) 0.9299
Gender (male/%) 27(56) 30(52) 0.8395
Weight (kg) 76(47-120) 84(50-160) 0.1227
Body surface area (adjusted) 1.8(1.45-2.2) 1.8(1.45-2.25) 0.8755
Melphalan dose (mg) 365(290-440) 365(290-45) 0.99
G-CSF dose(mcg/kg) 389(300-600) 413(300-600) 0.2584
Number of CD34 stem cell
infused
(million/kg) 6.57(2.97-20.9) 7.04(3.6-19.1) 0.4621
Documented infection (%) 6(12.5) 3(6) 0.468
Febrile neutropenia (%) 27(56) 20(41) 0.2204
Time to engraftment (days) 12(9-23) 13 (10-26) 0.0338
Engraftment > 14days (%) 8(17) 16(33) 0.0521
Total number of G-CSF doses
(mean/days)
9.42(6-24) 9.8(5-24) 0.5109
Length of stay(days) 16(13-51) 16(12-27) 0.4118
Elevated temps(>100.5) for
> 48 hours
9(19) 5(10) 0.3864
Hospital mortality 0 1 0.99was observed for diagnosis, age, gender, weight, BSA, growth
factor dose or dose/kg, number of stem cells infused, number
of patients who developed febrile neutropenia or micro-
biologically proven infection or prolonged fever (>48 hours).
Median time to engraftment and delayed engraftment
(>14days) was signiﬁcantly longer in the TBO-treated
patients. There was no difference in overall length of stay or
hospital mortality.
TBO-ﬁlgastrim appears to be effective in reducing the time
of neutropenia and stem cell engraftment. However delayed
engraftment, especially as observed >14 days after stem cell
infusion,was observed signiﬁcantlymore often inTBO treated
patients compared to those treated with FGS. These results
require conﬁrmation through a large randomized trial.368
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Allogeneic hematopoietic stem cell transplantation is being
employed as a life-saving procedure for greater numbers of
patients each year. Outpatient, reduced intensity transplants
and haplo-matched transplants, recognition of limited efﬁ-
cacy for chemotherapy in high risk diseases, and extending
the age limit for adults have all contributed to the growing
numbers. As a consequence, the demand for donor screening
resources has also increased. The National Marrow Donor
Programs (NMDP) has published the Assessment Tool at
Workup that has been recommended for use in determining
eligibility of unrelated donors. In order to avoid the risk of
bias in determining eligibility of related donors, the same
criteria are being applied to them at many centers. As a
referral center for complex transplants and increasing
numbers of donors, we reviewed the outcomes of related
donor screening and need for “additional” testing.
All donors were evaluated through a nurse practitioner-
based clinic with physician backup. All donors were
evaluated for bone marrow as well as peripheral blood
donation regardless of the requested product. Sixty-two
related potential donors were screened at MSKCC from
February through September 2014. The median age was
48yrs and they were equally divided between males and
females. Their demographics and outcomes are described in
Table 1. Based on initial routine screening studies and
utilizing the NMDP guidelines 15 donors (24%) were deemed
eligible and cleared for donation; 6 were ineligible according
to the NMDP guidelines for the following diagnoses: sickle
cell trait, systemic lupus, multiple sclerosis, history of
cervical cancer, babesiosis, and brain arteriovenous
malformation. Forty-seven (76%) donors did not clear
initially and 45 required additional evaluation based on  1
abnormalities (Table 2). These may have included laboratory
or imaging studies, informal or formal subspecialty
consultation or “other studies” such as bone marrow
procedure. Notably only 1/14 foreign born donors cleared
following initial evaluation. Forty-four (71%) donors actually
donated, 4 of whom were deemed ineligible but were used.
In all but 13 cases, the additional testing led to clearance.
Table 1
Donor Demographics and Outcomes
Initial
Clearance
N¼15
Not Initially
Cleared
N¼47
Males 8 53% 23 49%
Age median (range) 47 (22-66) 49 (20-72)
Family
Single Donor Family 14 93% 38 81%
Multi Donor Family 1 7% 9 19%
Type
Haplo-identical 3 20% 11 23%
Identical 12 80% 36 77%
Foreign Born 1 7% 13 28%
Donated
Yes 13 87% 31 66%
Ineligible but donated 0 4
Ineligible for PBSC 1 2
No 2 13% 16 34%
Ineligible & Deferred 0 7
More suitable donor 2 2
Recipient delay 0 3
Incomplete clearance 0 2
Change in protocol 0 1
Lab abnormalities 0 1
Product
PBSC 4 31% 25 81%
BM 2 15% 4 13%
MD requested 1 2
Per NMDP 1 2
Lymphocytes 6 46% 1 3%
Combination 1 (PB and BM) 8% 1 (PB and
Lymph)
3%
End Eligibility
Eligible and donated 13 87% 27 57%
Ineligible and donated 0 4 9%
Eligible and did not donate 2 13% 5 11%
Ineligible and did not
donate
0 8 17%
Incomplete Eligibility 0 3 6%
Abbreviations: PBSC e Peripheral Blood Stem Cells; BM e Bone Marrow
Table 2
Additional Evaluations
Abnormal Consult Further Testing
EKG 15 13 3
Pits 5 5 4
LFTs 15 10 9
X-Ray 2 2 1
Urinalysis 10 4 8
Other 8
Abbreviations: EKG e Electrocardiogram; Pits e Platelets, LFTs e Liver
Function Tests, Neuro e Neurology
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S261Conclusions: 1) The process of donor clearance has become
more complex and resource demanding. 2) Care should be
taken in selecting donors for screening to avoid unnecessary
added costs to the transplant.369
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Background: Late cytomegalovirus (CMV) disease occurs in
about 6% of patients (R+ or D+/R-) who survive the ﬁrst threemonths after HCT. We have previously identiﬁed steroid
treatment after day 100 and CMV viremia before and after
day 100 as risk factors for late CMV disease. Little is known,
however, about the epidemiology and risk factors of
recurrent late CMV disease. The objectives of this study were
to describe the incidence, clinical characteristics, outcome,
and risk factors for the development of recurrent late CMV
disease.
Methods: We retrospectively analyzed medical records of
117 HCT patients, who developed CMV disease more than
100 days after their ﬁrst allogeneic HCT between 2001 and
2011.We evaluated all CMV disease events occurring be-
tween the ﬁrst late CMV disease and 2 years after HCT. Late
CMV diseasewas considered recurrent if it occurred at least 6
weeks after the ﬁrst late CMV disease.
Results: Among 117 patients with late CMV disease, 31
(26%) patients died within 6 weeks of diagnosis. Twelve of
the eighty-six (14%) surviving patients developed a sec-
ond late CMV disease event. Nine (75%) of the second late
CMV disease cases were observed in the same organ,
while three (25%) occurred in a different organ. There
were 6 (50%) cases of gastrointestinal (GI) disease, 5 (42%)
cases of pneumonia, and 1 (8%) episode of retinitis. Sec-
ond late CMV disease episodes occurred at a median of
147 days [range 52-351] after the ﬁrst late CMV disease
and 374 days [range 212-679] after HCT. In addition, there
were 4 cases of third late CMV disease (3 pneumonia
and 1 GI).
All of the patients were receiving systemic immunosup-
pressive therapies at the time they developed recurrent late
CMV disease. Nine of these twelve patients were undergoing
weekly surveillance for viremia by PCR testing after their ﬁrst
late CMV disease event. Two patients developed CMV disease
while receiving preemptive therapy for viremia. Three pa-
tients had low-level viremia below the threshold for starting
treatment. However, four (33%) of the recurrent late CMV
disease events (2 pneumonia, 2 GI) developed in the absence
of viremia.
Two (17%) of the 12 patients with recurrent late CMV
disease died within 6 weeks of their diagnosis; one addi-
tional patient died shortly after developing a third episode of
CMV disease, and the remaining 9 patients survived at least
to two years after HCT.
Conclusions: These data demonstrate that recurrent late
CMV disease is not a rare event after allogeneic HCT. Patients
who remain on systemic immunosuppressive therapy after a
ﬁrst episode of late CMV disease seem to be at particularly
high risk for recurrence. While preemptive treatment of
viremia might prevent some of these events, one-third of the
cases developed in the absence of viremia including 2 cases
of CMV pneumonia. Further study is warranted to prevent
the morbidity and mortality associated with this late
complication of HCT.TRANSPLANT DATA MANAGEMENT370
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